Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - clotrimazole and betamethasone dipropionate cream usp, 1%/0.05% (base) is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to epidermophyton floccosum , trichophyton mentagrophytes , and trichophyton rubrum in patients 17 years and older. none. teratogenic effects, pregnancy category c there are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream usp, 1%/0.05% (base) in pregnant women. therefore, clotrimazole and betamethasone dipropionate cream usp, 1%/0.05% (base) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. studies in pregnant

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to epidermophyton floccosum, trichophyton mentagrophytes, and trichophyton rubrum in patients 17 years and older. none. teratogenic effects pregnancy category c there are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream in pregnant women. therefore, clotrimazole and betamethasone dipropionate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. studies in pregnant rats with intravaginal doses up to 100 mg/kg (15 times the maximum

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

remedyrepack inc. - clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65), betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to epidermophyton floccosum, trichophyton mentagrophytes, and trichophyton rubrum in patients 17 years and older. none. teratogenic effects pregnancy category c there are no adequate and well-controlled studies with clotrimazole and betamethasone dipropionate cream in pregnant women. therefore, clotrimazole and betamethasone dipropionate cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. there have been no teratogenic studies performed in animals or humans with the combination of clotrimazole and betamethasone dipropionate. corticosteroids are generally teratogenic in laboratory animals when administered at relatively low dosage levels. studies in pregnant rats with intravaginal doses up to 100 mg/kg (15 times the maximum

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breastfeeding women not to apply betamethasone dipropionate cream (augmented) directly to the nipple and areola to avoid direct infant exposure [see use in specific populations ( error! hyperlink reference not valid. )] .

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - risk summary there are no data regarding the excretion of betamethasone dipropionate in breast milk, the effects on the breastfed infant, or the effects on milk production after topical application of betamethasone dipropionate cream (augmented) to women who are breastfeeding. it is possible that topical administration of large amounts of betamethasone dipropionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for betamethasone dipropionate cream (augmented) and any potential adverse effects on the breastfed infant from betamethasone dipropionate cream (augmented) or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use betamethasone dipropionate cream (augmented) on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breast

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone dipropionate - unii:826y60901u) - betamethasone dipropionate 0.64 mg in 1 ml - betamethasone dipropionate lotion (augmented) is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older. the total dose should not exceed 50 ml per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. betamethasone dipropionate lotion (augmented) is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

physicians total care, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone dipropionate - unii:826y60901u) - betamethasone dipropionate 0.64 mg in 1 g - betamethasone dipropionate gel (augmented) is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. treatment beyond two consecutive weeks is not recommended, and the total dose should not exceed 50 g per week because of potential for the drug to suppress the hypothalamic-pituitary-adrenal (hpa) axis. this product is not recommended for use in pediatric patients under 12 years of age. betamethasone dipropionate gel (augmented) is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

teligent pharma, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone dipropionate  lotion is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. betamethasone dipropionate lotion is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. risk summary there are no available data on betamethasone dipropionate lotion use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women that betamethasone dipropionate lotion may increase the risk of having a low birthweight infant and to use betamethasone dipropionate lotion on the smallest area of skin and for the shortest duration possible.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

a-s medication solutions - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

a-s medication solutions - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.